Politician trade (House)

Thermo Fisher Scientific (TMO): Rep. Val T. Hoyle (OR04) disclosed a purchase $1K–$15K

Rep. Val T. Hoyle (OR04) disclosed a purchase of Thermo Fisher Scientific in the $1K–$15K range.

$1,001–$15,000
Reported range · official band, not an exact amount
318 days
Disclosure lag
Traded
Oct 29, 2024
Disclosed
Sep 12, 2025

The story around this disclosure

Every dated public record OQRO holds about the company from 60 days before to 120 days after, oldest first. It shows what was going on; none of it is a stated reason for the trade.

  1. Mar 6, 2024CongressDisclosed purchase of TMO — reported range $1,001 - $15,000
  2. Sep 4, 2024CongressDisclosed sale of TMO — reported range $1,001 - $15,000
  3. Sep 10, 2024CongressDisclosed purchase of TMO — reported range $1,001 - $15,000
  4. Oct 1, 2024FDAFDA device clearance: The Sensititre 20 - 24 hour Haemophilus influenzae/Streptococcus pneumoniae (HP) MIC or Breakpoint Susceptibility System with ceftriaxone in the dilution range…
  5. Oct 9, 2024FDAFDA device clearance: The Sensititre 20 - 24 hour Haemophilus influenzae/Streptococcus pneumoniae (HP) MIC or Breakpoint Susceptibility System with Meropenem in the dilution range o…
  6. Oct 25, 2024Insider · 2 peopleInsiders: 2 sales (~$1.3M)
  7. Oct 28, 2024Insider · 1 personInsiders: 7 sales (~$5.5M)
  8. Oct 29, 2024Insider · 1 personInsiders: 6 sales (~$5.5M)

What came next

  1. Oct 30, 2024Insider · 1 personInsiders: 6 sales (~$5.5M)
  2. Oct 31, 2024Insider · 1 personInsiders: 6 sales (~$5.5M)
  3. Nov 1, 2024Insider · 1 personInsiders: 9 sales (~$3.3M)
  4. Nov 6, 2024Insider · 1 personInsiders: 10 sales (~$5.6M)
  5. Nov 7, 2024Insider · 1 personInsiders: 7 sales (~$5.6M)
  6. Nov 8, 2024Insider · 1 personInsiders: 5 sales (~$5.0M)
  7. Nov 26, 2024FDAFDA device clearance: The Sensititre 18-24 hour MIC or Breakpoint Susceptibility System with Daptomycin in the dilution range of 0.03-64 ug/mL
  8. Dec 2, 2024Insider · 1 personInsiders: 7 sales (~$5.3M)
  9. Dec 3, 2024Insider · 1 personInsiders: 7 sales (~$5.3M)
  10. Dec 5, 2024FDAFDA device clearance: The Sensititre 18-24 hour MIC or Breakpoint Susceptibility System with Linezolid in the dilution range of 0.25-32 ug/mL
  11. Dec 9, 2024InsiderDirector purchased ~$2.1K of TMO shares in the open market
  12. Dec 19, 2024FDAFDA device clearance: The Sensititre 18-24 hour MIC or Breakpoint Susceptibility System with Ceftobiprole in the dilution range of 0.008-16 ug/mL
  13. Jan 8, 2025FDAFDA device clearance: Applied Biosystems™ TaqPath™ COVID-19, Flu A, Flu B, RSV Select Panel
  14. Feb 3, 2025InsiderCFO sold ~$5.83M of TMO shares in the open market
  15. Feb 4, 2025Insider · 2 peopleInsiders: 2 sales (~$5.9M)
  16. Feb 10, 2025FDAFDA device clearance: The Sensititre 20-24 hour Haemophilus influenzae/Streptococcus pneumoniae (HP) MIC or Breakpoint Susceptibility System with Linezolid in the dilution range of…
  17. Feb 10, 2025FDAFDA device clearance: The Sensititre 20-24 hour Haemophilus influenzae/Streptococcus pneumoniae (HP) MIC or Breakpoint Susceptibility System with penicillin in the dilution range of…
  18. Feb 19, 2025InsiderDirector sold ~$8.4K of TMO shares in the open market
View the official recordHouse Clerk periodic transaction report

How to read House Clerk periodic transaction report

The STOCK Act is a 2012 US law that requires members of Congress, and some senior staff, to publicly report their stock trades, and those of their spouse and dependent children, within 45 days.

Full guide: What is the STOCK Act?

What else is on file for Thermo Fisher Scientific

For Thermo Fisher Scientific, OQRO holds 26 insider filings (SEC Form 4 or Form 144), 6 fund holdings reports (13F) and 5 federal contract awards dated in the last 90 days.

These are records OQRO holds, counted by their date, not a measure of how much trading took place. Routine paperwork such as option exercises and tax withholding is left out. Everything for the company is on its TMO page.

Other recent filings by Rep. Val T. Hoyle (OR04)

The full history of Rep. Val T. Hoyle (OR04) is on the profile page.

How this filing works

Explore the data

Common questions

Which member of Congress traded Thermo Fisher Scientific (TMO) stock, and how much?

Rep. Val T. Hoyle (OR04) disclosed a purchase of Thermo Fisher Scientific in the $1K–$15K range. Reported range, not an exact amount, Spouse account.

When did it happen, and when was it made public?

Traded: Oct 29, 2024. Disclosed: Sep 12, 2025. That is 318 days between the two dates.

Why is the amount a range and not an exact figure?

Members of Congress report each trade in a bracket set by law ($1,001 to $15,000, $15,001 to $50,000, and so on), never an exact amount. OQRO keeps the bracket as filed and does not estimate a figure inside it.

Where does this information come from?

From the House Clerk periodic transaction report, a public record. The link to the official record is on this page, and OQRO copies its figures without changing them.

What else has been disclosed about Thermo Fisher Scientific recently?

For Thermo Fisher Scientific, OQRO holds 26 insider filings (SEC Form 4 or Form 144), 6 fund holdings reports (13F) and 5 federal contract awards dated in the last 90 days. They are listed on the TMO page.

Does this mean TMO stock is a buy or a sell?

No. This page describes one public filing. A filing does not say why someone traded and is not a forecast, so OQRO gives no recommendation.

Is OQRO free?

Yes. Every page of OQRO is free with an account, which takes a minute with Google and needs no card. Only the AI assistant is paid.

Other disclosures at Thermo Fisher Scientific

Everything OQRO holds on this company is on its TMO page.

This is one filing. OQRO holds the rest

Insider trades filed with the SEC, stock trades disclosed by members of Congress, fund holdings from 13F filings and federal contract awards, each one in plain words next to its official filing. On this page it opens why the trade stands out, what the company did around that time, the price since, and every field of the form.

OQRO is free for everyone. No card, no trial

OQRO describes public disclosures and context calculated from them. It does not give personalized advice and does not recommend any transaction. How OQRO treats data